Categories Earnings, Health Care
Catabasis Pharmaceuticals (NASDAQ: CATB): Q4 2019 Earnings Snapshot
— Catabasis Pharmaceuticals, Inc. (NASDAQ: CATB) reported a net loss of $6.6 million or $0.55 per share for the fourth quarter of 2019, compared to a loss of $6.1 million or $0.85 per share last year. Analysts had forecast a loss of $0.61 per share.
— Being a development-stage biopharmaceutical company, Catabasis did nor record revenues in the December-quarter
— Research & Development expenses increased 16% year-over-year to $4.3 million during the three-month period
— At $2.5 million, selling, general and administrative expenses were up 4% from the year-ago period
— As of December 2019, cash, cash equivalents and short-term investments were $36.2 million, compared to $40.6 million as of September 2019
— Expects to fund operations through a potential NDA filing and into the third quarter of 2021, using available cash
— Expects to publish top results from the phase-3 PolarisDMD trial of edasalonexent, in Duchenne muscular dystrophy, in the fourth quarter of 2020
Most Popular
360 DigiTech (NASDAQ: QFIN) Q3 2021 Research Summary
The positive effects of widespread digitalization and e-commerce growth on China’s financial services industry became more pronounced during the pandemic as the movement restrictions drove more retail customers to online
Activision Blizzard (ATVI): Three reasons why this stock deserves to be on your radar
Shares of Activision Blizzard Inc. (NASDAQ: ATVI) were up 1.6% on Thursday. The stock has dropped 14% since the start of the year. The company has been in the news
IPO Alert: Here’s all you need to know about Remitly Global’s upcoming market debut
The emergence of technology-driven financial services is making people think beyond conventional banks when it comes to availing loans and transferring funds. In a move aimed at taking its business
